Novo Nordisk A/SLargo
NVO: Super-Duper-To-Go
Actualizado
Fundamentals:
An insulin and diabetes drug care company based in Denmark. Booming fundamentals, booming funds, great cashflow, stable earnings and accelerating sales. Pays a little dividend.
Technicals:
Shallow pb
uHd
extreme indicator
34%-50% pb
a-b-c pb completion
horizonal support
kijun bounce
strong volume today at support
Outlook:
Expected to hold for 8 to 12 months. Expected to double in price within 8 months. Target 260 within 12 months.
An insulin and diabetes drug care company based in Denmark. Booming fundamentals, booming funds, great cashflow, stable earnings and accelerating sales. Pays a little dividend.
Technicals:
Shallow pb
uHd
extreme indicator
34%-50% pb
a-b-c pb completion
horizonal support
kijun bounce
strong volume today at support
Outlook:
Expected to hold for 8 to 12 months. Expected to double in price within 8 months. Target 260 within 12 months.
Nota
NVO giving us a healthy retracement right at the beginning of Q2 an NFP Friday.
This might be the fourth week of negative retracement into longer-term support. If the price closes below 125, then there is potential for a weekly shallow pb trade. Besides this, I watch and wait and sit on my hands and let the market and history play out.
Nota
uHd and triangle breakout
Nota
Weekly hidden bullish divergence with an engulfing bullish candlestick at 38% fib support. NVO looks good on this weekly chart and set to rise in the coming weeks.
Target is still 260 within 12 months.
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.